Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia.
Am J Trop Med Hyg. 2011 Oct;85(4):724-31. doi: 10.4269/ajtmh.2011.10-0436.
A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.
急需一种能有效针对所有 4 种血清型的登革热疫苗。然而，先前暴露于黄病毒可能会影响安全性和免疫原性。这项开放、对照、2a 期研究在 35 名健康成年人中进行，这些成年人在 1 年前接种过单价、减毒活vero 细胞来源的登革热 1 型（VDV1）或 2 型（VDV2）疫苗或黄热病（YF）疫苗，或为黄病毒初免者。所有参与者均接受一剂四价登革热疫苗（TDV）的皮下注射，并随访 180 天。既往接种不会增加疫苗接种后的不良反应、实验室异常或疫苗病毒血症的发生率，但会增加对登革热病毒的中和抗体反应，这种反应持续到第 180 天。先前接种 YF 疫苗的参与者中，YF 抗体没有增加。先前接触 YF 或单价登革热疫苗不会对与这种 TDV 相关的安全性或病毒血症发生率产生不利影响，但会增加免疫原性。
